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ABSTR ACT: Magnetic resonance imaging (MRI), frequently with contrast enhancement, is the preferred imaging modality for many 
indications in children. Practice varies widely between centers, reflecting the rapid pace of change and the need for further research. Guide-
line changes, for example on contrast-medium choice, require continued practice reappraisal. This article reviews recent developments in 
pediatric contrast-enhanced MRI and offers recommendations on current best practice. Nine leading pediatric radiologists from interna-
tionally recognized radiology centers convened at a consensus meeting in Bordeaux, France, to discuss applications of contrast-enhanced 
MRI across a range of indications in children. Review of the literature indicated that few published data provide guidance on best practice 
in pediatric MRI. Discussion among the experts concluded that MRI is preferred over ionizing-radiation modalities for many indications, 
with advantages in safety and efficacy. Awareness of age-specific adaptations in MRI technique can optimize image quality. Gadolinium-
based contrast media are recommended for enhancing imaging quality. The choice of most appropriate contrast medium should be based on 
criteria of safety, tolerability, and efficacy, characterized in age-specific clinical trials and personal experience.
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Introduction
Magnetic resonance imaging (MRI) is an important modal-
ity for diagnosing and monitoring a wide range of child-
hood diseases. Gadolinium-based contrast media enhance 
the efficacy of MRI for many applications. Until recently, 
evidence to direct best practice in pediatric MRI was based 
largely on adult studies, but pediatric-specific data are now 
increasingly available. However, a number of open issues 
remain, indicated by the large variations in practice between 
centers.
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This review article reports current perceptions on the 
practice of MRI in children, based on discussions and consen-
sus statements developed at an international expert meeting, 
attended by nine pediatric radiologists from internationally 
recognized radiology centers in Canada, Germany, Italy, 
South Korea, Spain, Sweden, and the UK, combined with 
follow-up collegiate revisions during manuscript develop-
ment. The review is not intended to be comprehensive, but 
focuses on areas of topical interest while noting areas for fur-
ther investigation. Reflecting recent clinical trial activity, the 
role of gadolinium-based contrast media in pediatric MRI 
receives particular attention.
The recommendations expressed in this review are inte-
nded solely as general guidance on best practice in pediatric 
MRI. Clinical decision-making must be based on the require-
ments of each patient, guided by the latest sources of informa-
tion available, including local guidelines and newly published 
trial data.
Advantages of MRI in pediatric radiology. Imaging 
modalities available in children may be classified as invasive 
(eg, intra-arterial digital subtraction angiography and 
endoscopy) and noninvasive (eg, ultrasound, X-ray, computed 
tomography [CT], nuclear medicine, positron emission 
tomography, and MRI). In practice, all these techniques are 
routinely employed, since no single modality can fully replace 
another. The preference for particular methods depends on the 
local availability of each modality and on the clinical scenario, 
taking into account the degree of invasiveness and potential 
associated morbidities, including those from exposure to 
ionizing radiation.
CT has developed rapidly as an imaging modality. This 
is explained by the increasing availability of multidetec-
tor CT scanners and the ability of the technique to provide 
rapid, high-quality image acquisition. However, the radiation 
associated with CT represents a major concern, particularly 
for children, who are more sensitive to the effects of ioniz-
ing radiation than adults.1,2 The risk of cancer due to radia-
tion exposure is two to three times higher in children than in 
adults.1,2 While specific protocols have been developed for CT 
with scanning parameters specifically designed for children, 
the best way to reduce the radiation dose to pediatric patients 
is to avoid unnecessary CT exams.3 Thus, alternative imaging 
modalities without ionizing radiation exposure, commonly 
ultrasound and MRI, are preferred for diagnosis in pediatric 
clinical practice.
Ultrasound is easy to perform and provides real-time 
imaging of dynamic processes at relatively low cost. In addi-
tion, there is no need for sedation. However, ultrasound does 
not always suffice to confirm or exclude pathology, charac-
terize lesions, or display exact anatomic limits to plan patient 
management.
MRI has the capacity to provide high-resolution images 
of tissue anatomy in multiple planes, combined with quan-
titative functional imaging. A particular advantage of MRI 
is its ability to differentiate soft tissues. The main drawbacks 
of MRI relevant to pediatric imaging are the potential need 
for sedation or anesthesia and the limited availability of MR 
equipment tailored to pediatric use outside specialized cen-
ters. The long sequence time utilized in conventional MRI has 
the potential drawback of making timed scanning difficult, 
for example when both an arterial and a portal venous phase 
scan of the liver is required. This drawback has been mini-
mized with newer, shorter acquisition sequences designed for 
contrast-enhanced MRI, such as VIBE or FLASH.
Consensus statement. MRI offers the major safety advantage 
of a lack of ionizing radiation, combined with efficacy benefits 
of excellent three-dimensional anatomic representation, tissue 
characterization, and quantitative/functional capabilities.
Applications of MRI in pediatric radiology. MRI is an 
established technique for the detection, evaluation, staging, 
and follow-up of a range of disease processes.4 MRI provides 
data on anatomy and physiologic processes (flow, diffusion, 
and perfusion) with high sensitivity and specificity.
The extensive experience of MRI in adult patients is 
often—but not always—directly transferable to the pediat-
ric population. Pediatric MRI presents challenges that relate 
primarily to: (a) anatomic differences in structures, including 
developmental changes, (b) different physiologic parameters, 
(c) characteristic diseases of this age-group, and (d) behaviors 
typical of this age-group that limit adequate performance of 
an MRI study.
Specific applications of MRI in children include anatomic 
imaging of the central nervous system (CNS), chest, abdo-
men, pelvis, and musculoskeletal tissue for disorders includ-
ing congenital malformations, tumors, infections, metabolic 
disorders, and inflammatory diseases (Table 1).4 Additional, 
quantitative information for the characterization of disorders 
can be provided by techniques including diffusion-weighted 
MRI, MR spectroscopy (MRS), and perfusion MRI.5–8 
 Diffusion-weighted MRI has particular applications to detect 
early cerebral ischemia and infarction, to differentiate intra-
cranial cysts from solid masses, to diagnose encephalopathy 
or encephalitis, and to identify congenital anomalies; recent 
applications based on technological developments extend 
beyond the CNS to include tissue characterization (eg distin-
guishing benign from malignant tissue), organ function (such 
as for liver and kidneys), and monitoring response to therapy 
in extra-neurological tumors.9,10 MRS combines information 
from MRI with nuclear magnetic resonance to provide infor-
mation on tissue metabolites that can help differentiate abnor-
malities such as certain types of tumors. MRS has been used 
to evaluate neurodegenerative diseases, including early detec-
tion and monitoring of response to therapy for demyelinating 
diseases (where N-acetyl aspartate [NAA] and choline levels 
may be increased), as well as in epilepsy and trauma (where 
NAA levels may be decreased); a widespread role for MRS 
is not yet established.11–13 Perfusion MRI, such as by arterial 
spin labeling (ASL), assesses relative cerebral blood flow and 
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Table 1. applications of pediatric MRi by body region.
BODY REGION APPLICATIONS OF MRI ADVANTAGES OF MRI MR PROTOCOL
Brain and spine –  tumors (eg, ependymoma, medulloblas-
toma, cerebellar low-grade astrocytoma)
– congenital malformations
– Demyelinating diseases
– neurodegenerative disease
– Inflammatory diseases
– epilepsy
extensive experience of 
anatomic and functional 
characterization of cns 
pathologies
Brain: axial t2-weighted, coronal 
FLaiR, and coronal and sagittal 
t1-weighted images
spine: sagittal, fast spin-echo 
t1- and t2-weighted sequences
gadolinium enhancement used in 
suspected inflammation, tumors/
metastases, white matter disorders, 
neurocutaneous disorders
chest –  Pulmonary diseases of alveolar infiltration 
or exudation patterns (eg, segmental  
pneumonia or bronchopneumonia,  
pulmonary edema)
– tumors
–  Interstitial pulmonary diseases, fibrotic 
processes
– Lung malformations
superior visualization 
of interstitial processes, 
inflammatory disease
t2-weighted (turbo spin echo)
t1-weighted spin echo or 
3D- gradient echo sequence
after applying gadolinium contrast 
(if suspicion of abscess, assess-
ment of fibrosis activity)
combination of cardiac and ventila-
tor gating often required (use fast 
 imaging technique)
cardiovascular 
system
–  congenital malformations (eg, shunts,  
fistulae, regurgitant valves)
Provision of 3D ana-
tomic and hemodynamic 
information, beyond 
echocardiography and 
catheterization
Breath-held, ecg-gated, bal-
anced steady-state free precession 
(b-ssFP) cine image
gadolinium enhancement used in 
b-ssFP and MRa
abdomen – acute abdomen
– Unexplained abdominal pain
– appendicitis
–  Inflammatory bowel disease (Crohn’s 
 disease, ulcerative colitis)
– Motility disorders
–  congenital gi malformations, eg, biliary 
atresia, cloacal malformations
– gi tumors
– Pancreatitis
– ovarian pathology
– trauma
anatomic depiction of 
complete abdominal 
organ systems
coronal t2-weighted or stiR 
images in combination with axial 
t2-weighted and/or fat suppressed 
(stiR) t2-weighted imagesenterography (oral con-
trast distention of the 
bowel combined with 
intravenous gadolinium) 
provides increased 
sensitivity for bowel wall 
abnormalities
Further sequences obtained 
according to underlying pathology
intravenous hyoscine or glucagon to 
reduce peristalsis
gadolinium enhancement used 
in suspected inflammatory bowel 
disease
Musculoskeletal 
system
–  skeletal, congenital, and  developmental 
disorders (eg, hip dysplasia, Meyer’s 
dysplasia)
–  Rheumatic diseases (eg, juvenile 
spondyloarthropathies)
–  trauma (bone fracture, tendon, and muscle)
– Bone tumors (benign, malignant)
–  soft tissue masses (eg, vascular malforma-
tions, cysts, fibromatous tumors, neurofibro-
mas, soft tissue malignancies)
Versatile depiction of 
bone marrow, cartilage, 
joints, and soft tissues 
to identify and localize 
pathology
t1-weighted, t2-weighted, and pro-
ton density sequences (at least one 
combined with fat saturation), short 
tau inversion recovery sequence
t1-weighted images performed with 
gadolinium contrast
genitourinary tract 
(urography)
– congenital anatomic abnormalities
– Vesicoureteric reflux
– hydronephrosis
– obstructive uropathy
evolving technique for 
generating high-quality 
anatomic scans (kidneys, 
ureters, and bladder) and 
renal function assess-
ments (eg, split renal 
function and drainage)
T2-weighted imaging (static-fluid 
MR urography)
t1-weighted fat suppressed 
post-contrast imaging (excretory 
urography)
infections cns
–  Bacterial intracranial infection (eg, epidural 
and subdural empyema, meningitis,  
pyogenic abscess)
–  spinal infection (eg, spondylodiscitis,  
epidural abscess)
–  Viral meningoencephalitis (eg, herpes  
simplex virus)
– hiV
non-cns
– Musculoskeletal (eg, osteomyelitis)
– gastrointestinal (eg, cholangitis)
– Vascular (eg, vasculitis)
Sensitive and specific 
imaging, providing early 
diagnosis
t1- (pre- and post-gadolinium) and 
t2-weighted images
gadolinium enhancement provides 
additional information for differential 
diagnosis
(continued)
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Table 1. (Continued).
BODY REGION APPLICATIONS OF MRI ADVANTAGES OF MRI MR PROTOCOL
Metabolic disorders 
and malformations
–stroke (arterial, venous, hemorrhagic)
–hypoxic–ischemic brain injury
– hereditary metabolic diseases (eg, peroxi-
somal disorders, lysosomal storage disor-
ders, disorders of amino acid and organic 
acid metabolism)
–Brain malformations
–Vascular malformations
Depiction of small/subtle 
pathology
axial t2-weighted turbo spin echo, 
an axial FLaiR, t2*-weighted 
gradient-echo sequences, diffusion-
weighted imaging and sagittal 
t1-weighted acquisition
gadolinium-enhanced t1-weighted 
images for inflammatory diseases 
or tumors
Whole body –tumors
– Multifocal lesions (eg, metastases, storage 
disorders, soft tissue disorders, multifocal 
osteomyelitis)
–Fever of unknown origin
–non-accidental trauma
3D-anatomic visualiza-
tion for determining loca-
tion and extent of lesions; 
functional/quantitative 
capabilities
stiR or fat suppressed t2 spin 
echo, diffusion-weighted imag-
ing, fat suppressed t1 spin 
echo, 3D-spoiled gradient echo 
sequences in arterial or portove-
nous phase following gadolinium 
contrast, fat suppressed t1 se 
(post-gadolinium)
volume, and can be used to better characterize tumors and 
detect areas of ischemia during stroke.14 Increasingly, func-
tional and quantitative techniques are being incorporated into 
standard MRI protocols.15
The majority of MRI procedures in children are for CNS 
disorders, most frequently congenital malformations, inflam-
matory diseases, epilepsy, stroke, or brain tumors; the recent 
availability of age-specific MRI templates for neuroimaging 
during pediatric development provides a reference resource for 
normal structural changes over time.16–18 Also common are 
abdominal MRI to identify tumors and infections, and mus-
culoskeletal MRI to diagnose arthritis, osteomyelitis, other 
bone and soft tissue infections, and tumors. MRI of the cardio-
vascular system is being more widely used, both alone and in 
combination with echocardiography, as it provides exceptional 
visualization of three-dimensional anatomy and reliable mea-
sures of function.19 Additional emerging applications for pedi-
atric MRI include urography, enterography (see Fig.  7), and 
cine airway imaging.20 Whole body MRI, while technically 
demanding in children, can aid detection of disease through the 
entire body, with particular applications for locating multifocal 
lesions (eg, metastases, storage disorders, and multifocal osteo-
myelitis) and determining the extent of soft tissue disorders.21,22
MRI has therefore become the modality of choice, in 
place of CT, in children because of the variety and types of tis-
sue contrast it provides, combined with its non- invasiveness. 
Use of MRI is recommended in most clinical scenarios, par-
ticularly in follow-up to avoid repeated radiation exposure. 
Nonetheless, there are specific exceptions where other imag-
ing modalities are preferred, such as the following examples:
•	 Lung pathology: conventional X-ray and CT are preferred
•	 Pathology of small bones (eg, temporal bone) and cortical 
bone lesions: CT is preferred in the emergency setting. 
MRI may misdiagnose lesions, but is useful for imaging 
complications as in acute mastoiditis23
•	 Congenital heart disease in the newborn: CT offers 
greater speed in diagnosis
•	 Multitrauma: CT offers greater speed and, usually, no 
requirement for sedation.
The selection of MRI over ionizing-radiation modalities 
is based on the availability of high-quality and high-field MR 
scanners, coils, and software and reflects the expertise and 
experience of the operator. Despite variability between centers 
in the current first-choice indications for imaging techniques, 
MRI will likely become the modality of choice for most indi-
cations in future.
Consensus statement. MRI is the modality of choice for 
diagnosing a broad spectrum of clinical disorders and for 
evaluating abnormalities detected at ultrasound or X-ray. 
Alternative imaging modalities currently have advantages 
in specific situations. In future, MRI is likely to become the 
first-choice modality across most indications.
Practical issues in pediatric MRI.
Preparing the child. Aspects of the MRI procedure, such as 
the enclosed space and the loud noise from the scanner, can cause 
anxiety in children, especially those of younger age. An adult 
family member or guardian should be encouraged to stay with 
the child during the scan. Child life specialists are a resource 
available at many hospitals, offering expertise to assist pediatric 
patients and their parents/guardians to cope with the procedure 
and to provide educational information, as required.24
Sedation or anesthesia is effective for reducing anxiety 
and movement in approximately 90% of cases. Sedatives/ 
hypnotics at the lowest possible dose are preferred.25 Widely 
used agents for sedation include:
•	 Propofol: administered by infusion at 2–5 mg/kg/h for 
sedation, with advantages of short induction (2 min) 
and recovery (8 min) times and a low incidence of 
complications.26,27
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•	 Dexmedetomidine: administered as a loading dose 
(2–3 µg/kg, over 10 min) and maintenance infusion 
(1–2 µg/kg) for sedation. Dexmedetomidine is unsuitable 
in patients with cardiac compromise; however, less air-
way support may be required for dexmedetomidine than 
for propofol.27,28
•	 Pentobarbital: oral or rectal dosing at 3–6 mg/kg, with 
a time to onset of 15–60 min and duration of effect 
60–120  min.27 Pentobarbital may be associated with 
 cardiovascular and respiratory depression.
•	 Chloral hydrate is not recommended at many centers, 
based on high incidences of nausea and vomiting, long 
recovery time, postoperative agitation, and high failure 
rates for MRI.27
General anesthesia (GA) may be chosen in selected chil-
dren (eg, with congenital heart defects or airway abnormali-
ties) and particularly in patients requiring long-duration scans 
(eg, with staging investigations, in cases of malignancies) or 
with a history of failed sedation.29 In small children, the pre-
dictable safety of GA may be preferred over deep sedation; 
sedation also has a lower success rate.27,30
Sedation and GA carry risks of complications that 
necessitate continuous monitoring.25 Adverse events (AEs) 
of sedation, including respiratory depression and hypoxemia, 
may occur in up to 20% of children. Conversely, inadequate 
sedation, potentially leading to failure of the MRI procedure, 
is reported in 13% of children.31 GA can impact adversely 
on data acquisition, such as brain chemistry assessments in 
MRS.32 Sedation and GA are also costly, may be impracti-
cal, and require a recovery period. For these reasons, sedation 
and GA are generally avoided where possible and alternative 
approaches are employed. The choice of the agent and tech-
nique used for sedation or GA reflects the experience of the 
practitioner, potential constraints imposed by the patient and 
procedure, the availability of appropriate monitoring equip-
ment (including electrocardiography, pulse oximetry, blood 
pressure, and body temperature assessments), and the institu-
tional policies in place.27 All members of the anesthetic team 
should be familiar with MRI-specific safety issues and the 
requirements of the diagnostic procedure before induction.33
Familiarizing the child and parent or guardian with 
MRI can facilitate the MR procedure. Verbal explanation 
supported by explanatory literature or cartoons (for very 
young children) represents good practice. Novel approaches 
to familiarizing young patients include interactive online pro-
grams and recordings of MRI scanner noise that can be played 
at home.34 Exposing the patient to “mock MRI” using a scan-
ner “shell” has been reported effective.35,36 Audio and video 
entertainment can be integrated into the scanner to distract 
the patient during the procedure.
Another approach that is especially suitable for infants 
is to time the scan to coincide with normal sleep patterns or 
following breastfeeding, or to encourage the child to remain 
awake until the scan, aiming for natural sleep during the 
examination.33 A feed-and-sleep technique with use of swad-
dling to reduce movement (“feed and swaddle” protocol) 
can successfully avoid the need for sedation in neonates and 
infants.37–40 Preparing the child before transfer to the scanner 
(eg, removing intravenous therapy equipment and monitors) 
can help lower anxiety. The anxiety and pain of procedure-
related injections can be reduced by using anesthetic cream at 
the venipuncture site and, in inpatients, performing intrave-
nous access on the ward.
Many centers offer their own recommendations on prac-
tical methods for preparing the child, including information 
on food intake before the scan, what to bring to the appoint-
ment, the duration of the test, and how the scan results will 
be communicated. Adult family members or guardians can be 
encouraged to become familiar with these recommendations.
Consensus statement. Staff and environment should help 
the patient and parent or guardian feel secure and remain calm 
during the MR examination. Patients can be familiarized 
with the procedure before the scan. Younger children may 
be encouraged into natural sleep during the examination. 
In selected cases, sedation or GA may be used, according to 
institutional preference.
Performing the pediatric MR examination.
Scanning times. As described elsewhere, a short scan time 
is a desirable objective in pediatric MRI. Hardware-based 
strategies to minimize scan times include high field-strength 
magnets and multi-channel phased-array coils for enhanced 
image quality. Software-based strategies include fast imaging 
sequences (mentioned in Table 1), parallel image processing, 
compressed sensing, and respiratory triggering or combined 
respiratory-cardiac triggering methods.41,42 MR applications 
that utilize parallel imaging with potential to reduce scan 
times in wider practice include contrast-enhanced dynamic 
imaging, volumetric (3D) T2-weighted imaging, and single 
shot imaging (SSFSE, HASTE).42 Continuing advances in 
hardware and software are predicted to reduce scan times 
further in the future.
Equipment. Knowledge of the field of view of the 
imaging coils available in the department dictates coil 
choice. The size of the imaging coil should be approximately 
1.5 times the size of the body region imaged. Institutions that 
scan children frequently may consider obtaining a selection 
of dedicated coils with fields of view that fit the range of 
anatomy to be scanned.43 Use of an array of multichannel coils 
permits parallel imaging, which can substantially reduce the 
duration of pediatric MRI, particularly of the abdomen and 
cardiovascular system.
The progressive introduction of 3 Tesla (T) imaging 
offers improved spatial resolution and signal-to-noise ratio 
(SNR) compared with 1.5 T.44 3 T imaging may be particu-
larly beneficial for children because of their smaller body size, 
although specific coils are required (detailed in21). Low-field 
MRI (0.2–0.5 T) cannot be recommended in children.
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Consensus statement. To achieve optimal resolution, coils 
should be selected according to the body region. At minimum, 
a 1.5 T system should be used, but a 3 T system will provide 
superior imaging if specific coils are available.
MRI protocol. The procedures used and their sequence in 
the protocol have a substantial impact on the efficacy of the MR 
examination. Selection of the optimal protocol for individual 
patients is complex, especially in children. Continued changes 
in technology and the relative rarity of some disorders largely 
preclude an evidence-based approach to protocol choice. At 
individual centers, factors influencing protocol choice include the 
equipment available, staff experience, and guidelines in place.
Fluid-attenuated inversion-recovery (FLAIR) imaging is 
an important component of MR examination of the brain in 
adults, but FLAIR sequences are not routinely recommended 
for patients under 1 year old, because pathology may be masked 
by hyperintense unmyelinated white matter. Also, GA with 
high content of oxygen may increase the subarachnoid signal 
in FLAIR imaging, which can falsely suggest bleeding.
T1- and T2-weighted sequences are recommended in 
all age-groups. In acute situations, in all pediatric age-groups 
(beginning in the newborn), diffusion-weighted imaging and 
gradient echo imaging are necessary for diagnosing ischemic 
or hemorrhagic stroke. Gradient echo imaging, by being 
less  susceptible to motion artefacts, also has a place in bowel 
 imaging. Time-of-flight angiographic and venographic tech-
niques have value in assessing vascular abnormalities. Recent 
studies of contrast-enhanced MR angiographic (MRA) and 
venographic (MRV) techniques suggest benefit in the assess-
ment of vascular pathology.45,46 MRS can be used in cases of 
suspected metabolic disorder and for differentiating tumor 
and inflammation.
Additional protocol components may include inversion 
recovery with inversion times set to suppress fat (STIR) in 
CNS, abdominal, and musculoskeletal imaging; time-resolved 
angiography for dynamic angiographic data (TWIST, Sie-
mens; TRICKS, GE Healthcare; 4D-TRAK, Philips; Freeze 
Fame, Toshiba; and TRAQ , Hitachi); and volumetric inter-
polated breath-hold examination for contrast-enhanced tho-
racic, vascular, and abdominal imaging (VIBE, Siemens; 
LAVA, GE Healthcare; THRIVE, Philips; and Quick 3D, 
Toshiba) (see Fig. 6).
Readers are referred to recent reviews and recommen-
dations for guidance on specific protocols in neurology,15 
cardiology,19 respiratory medicine,47 gastroenterology,6 mus-
culoskeletal disorders,5 and whole body imaging.48
Protocol selection—experience in clinical practice. 
Representative case studies of MRI procedures in children for 
indications including CNS, circulatory, abdominal, and soft 
tissue disorders are shown in Figures 1 and 2.
Figure 1. choroid plexus carcinoma of right ventricle, in 2-year-old girl with turner syndrome, polycystic kidney, nephrolithiasis, and posttraumatic skull 
fracture with cephalohematoma over right hemisphere. technique: head coil, 1.5 t, gadobutrol 1 mL by manual injection. Protocol: FLaiR, t2 tse, t1, 
t1 gd. slice thickness 3–4 mm. Findings: Pre-contrast t2-weighted (B, C, D) and FLaiR (A) images showed a brain tumor with inhomogeneous signal 
in right ventricle. surrounding parenchyma of the right hemisphere showed bright signal in t2. Post-contrast (F, G, H): inhomogeneous enhancement in 
the tumor with cystic changes compared with pre-contrast images (E). conclusions: MRi provided differential diagnosis of plexus carcinoma vs. plexus 
papilloma. courtesy Dr g hahn.
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Figure 2. hemangioma in 7-month-old girl with large soft tissue mass in forehead. technique: head coil, 1.5 t, gadobutrol 0.6 mL by manual injection. 
Protocol: t2, t1, t1 gd. slice thickness 1.2–3.0 mm. Findings: 3 × 4 × 2 cm tumor attached to the bony calvarium on left side on t2-weighted images 
(A, B). intermediate signal on t1 (C) with small spots of higher signal and small tubular hypointensities (signal voids) within the mass. after administration 
of gadobutrol, the tumor enhanced uniformly, except for central vascular structures (D). No obvious intracranial extension or other pathologic findings. 
conclusions: MRi with gadolinium enhancement was valuable for determining the extent of disease and associated anomalies and for excluding 
malformations of the brain. courtesy Dr e stokland.
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Table 2. Practical suggestions for pediatric MRi: equipment and 
protocol.
TECHNICAL RECOMMENDATIONS
•	 select protocol sequences and parameters on a patient-by-
patient basis
•	 Use the smallest coil possible to maximize snR
•	 Minimize the examination time
•	 Perform the most critical sequences first
•	 Key sequences: t1/t2, fast spin echo, gradient echo, FLaiR/
stiR/diffusion
•	 slice thickness:
•	 Brain: 1-year-old: 3–4 mm, school-age children: 
4–5 mm
•	 orbits: 2–3 mm
•	 spine: 3 mm
•	 Pituitary: 2–3 mm
•	 Body: 4–6 mm
•	 Musculoskeletal system: 3–5 mm
•	 angiographic sequences: 1–2 mm
•	 Keep voxel size large enough for adequate snR
PATIENT CARE RECOMMENDATIONS
•	 Use ear plugs or headphones to protect the patient’s ears
•	 apply anesthetic cream to reduce pain at venipuncture site
•	 encourage natural sleep to reduce anxiety and movement
•	 sedation/ga, if required, should follow local guidelines
•	 an adult family member should accompany the child during 
the scan
Abbreviations: FLAIR, fluid-attenuated inversion-recovery; GA, general 
anesthesia; MRi, magnetic resonance imaging; snR, signal-to-noise ratio; 
stiR, short inversion-time inversion recovery; t, tesla.
Practical suggestions for performing MRI in children, 
based on expert discussions, are summarized in Table 2.
Consensus statement. MRI protocols should be selected on 
an individual basis, adjusting parameters appropriately to the 
patient’s size and condition.
Applications of contrast-enhanced MRI in pediatric 
radiology.
Criteria for use of contrast enhancement. In many indi-
cations, gadolinium-based contrast media provide additional, 
clinically relevant information when compared with native 
MRI. Discussion of contrast enhancement in pediatric MRI 
can be divided into CNS (brain and spine) and non-CNS 
applications.
Contrast-enhanced brain and spine MRI. At many 
centers, gadolinium-based contrast enhancement represents 
the clinical standard for imaging CNS disorders, providing 
additional information on the location, type, and stage of 
lesions for diagnosis and treatment planning.49,50 Contrast-
enhanced MRI improves the accuracy of differential 
diagnosis between CNS tumors and alternative diseases, 
such as demyelinating disorders (multiple sclerosis and acute 
disseminated encephalomyelitis) and abscesses.7 Evaluation 
of tumors is improved with contrast enhancement not 
only by looking at enhancement patterns but also for 
detecting metastasis indicating the malignant nature of 
CNS masses. Besides its role in imaging tumors, contrast-
enhanced MRI is a valuable tool in characterizing CNS 
infections; vascular anomalies and disorders51; neurological 
pathologies (including demyelinating diseases and neu-
rodegenerative disease); and neurocutaneous syndromes 
(such as neurofibromatosis). For bacterial infections such 
as men ingitis and meningoencephalitis, contrast-enhanced 
MRI assists in monitoring the response to therapy and the 
dev elopment of complications such as ischemic lesions, 
abscess, or empyema.4,52,53 Contrast-enhanced MRI also 
has an important role in the diagnosis of intracranial 
tuberculosis and bacterial spondylodiscitis, and in detecting 
and monitoring viral infection and immune-mediated 
inflammation. Inflam matory disorders such as Guillain–
Barré syndrome are better identified with contrast than 
on non-enhanced studies with identification of enhancing 
nerve roots.54,55
In addition to providing conventional images based on 
anatomy, MRI can characterize functional and metabolic fea-
tures of cerebral tissue. Functional imaging techniques (eg, 
dynamic susceptibility contrast, DSC) can provide informa-
tion on the relative cerebral blood volume (rCBV), which may 
assist in identifying the neovascularization associated with 
tumor growth and help to guide biopsy by localizing the most 
capillary-dense portion of a tumor. DSC is the current MR 
imaging-based technique of choice for in-vivo quantification 
of perfusion parameters in normal or tumor tissue.56 Fol-
lowing treatment, contrast-enhanced MRI can detect lesion 
recurrence before symptoms develop, increasing the likeli-
hood of an improved outcome.
Contrast-enhanced non-CNS MRI. Gadolinium-based 
contrast-enhanced MRI is widely used for characterizing infec-
tions; inflammatory processes; neurocutaneous syndromes 
(eg, neurofibromatosis); abdominal, musculoskeletal, and soft 
tissue disorders, including tumors; cardiovascular disease and 
malformations; and metabolic disease. Contrast enhancement 
can be especially helpful for defining small or subtle lesions or 
foci of inflammation that are unclear on native scans.57
MR urography with contrast enhancement has become 
an accepted substitute for intravenous urography and 
 scintigraphy, with the capability to combine in a single 
study the assessment of morphology and function, includ-
ing the concentrating and excretory functions of each kid-
ney.58 Furosemide is administered at the beginning of the 
study to enhance dilation of the urinary tract and aid in 
the  distribution and  dilution of gadolinium-based contrast 
medium. A  typical protocol includes pre-contrast T1  and 
T2 images through the kidneys, ureters, and bladder, fol-
lowed by  gadolinium-based contrast medium administration 
for contrast enhancement and dynamic contrast-enhanced 
T1 imaging of the urinary tract. MR urography is  particularly 
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useful for investigation of hydronephrosis and  malformations 
of the ureteropelvic unit.59,60
Contrast-enhanced MRA is as effective as digital subtrac-
tion angiography for the evaluation of vascular diseases.51,61 
Pediatric applications of contrast-enhanced MRA include the 
characterization of congenital cardiovascular abnormalities 
of the chest, abdomen, and extremities, with superiority over 
cine angiography or echocardiography.62–65
Typically, local and national guidelines are in place to 
advise on use of contrast enhancement in different indica-
tions. While contrast enhancement offers additional infor-
mation relative to unenhanced MRI in the great majority of 
indications, contrast media are not routinely employed for 
certain metabolic and musculoskeletal (eg, suspected herni-
ated disk, bone fracture) MR imaging procedures. In chil-
dren with severely impaired renal function or on dialysis, or 
in very young children, contrast medium use should be sub-
jected to careful risk/benefit assessment, because of the low 
risk for nephrogenic systemic fibrosis (NSF, discussed below). 
For these groups, unenhanced MRI or other imaging tech-
niques should be considered; for example, studies show that 
diffusion-weighted MRI has potential applications for the 
characterization of kidney function and pathology in patients 
with renal insufficiency.66 Guidelines should ideally allow 
flexibility in the use of contrast media to reflect the complexi-
ties of clinical practice. The injection method, speed, timing, 
and flush should all be decided on an individual patient basis.
Consensus statement. Gadolinium-based contrast media 
provide reliable enhancement on T1-weighted images and 
represent the clinical standard in many pediatric MRI 
protocols. Gadolinium-based contrast media improve the 
localization, characterization, and staging of tumors/lesions, 
the differentiation of inflammatory and infective disorders, 
and the performance of MRA.
Considerations in contrast medium choice. Readers 
are referred to local guidelines and prescribing information 
for details on the contrast media approved for use in different 
age-groups. Table 3 summarizes selected properties of 
gadolinium-containing contrast media.
Readers are referred to recent reviews for a discussion 
of the potential role of organ-specific contrast media, such as 
gadoxetate disodium for hepatobiliary imaging, in pediatric 
patients.67
Clinical Trials in Pediatric MRI
Until recently, few well-controlled clinical trials were avail-
able to guide contrast medium choice in pediatric MRI, in 
 contrast to the extensive experience in adults. The trials that 
were available typically included low numbers of pediatric 
patients in limited indications.68–71
Studies to characterize contrast agent use specifically in 
pediatric MRI include pharmacokinetic and safety investiga-
tions of the 0.5 molar gadolinium-based contrast media72–74 
and the 1 molar agent, gadobutrol.75,76
Factors Influencing Contrast Medium Choice
Safety. Safety is the primary determinant in the choice 
of contrast medium. Safety considerations for each contrast 
medium include the stability of the molecule, AEs, and the 
pharmacologic profile.
Chelate stability. Gadolinium-based MRI contrast media 
can be classified by their molecular structure into linear and 
macrocyclic groups. Agents with a linear structure have a 
polyamino-carboxylic acid “backbone” that wraps around, 
but does not fully enclose, the gadolinium ion, whereas 
macrocyclic compounds (gadobutrol, gadoterate meglumine, 
and gadoteridol) possess a tetra-aza “cage” that surrounds 
the ion.
In-vitro experiments under physiologic conditions show 
that macrocyclic agents are more stable and less prone to 
release gadolinium ions than linear compounds (Fig. 3).77 
Gadolinium-containing contrast media have been linked to 
the condition of NSF in patients with renal impairment.78,79 
The stability of the chelate appears to have a role in the devel-
opment of NSF.
Recently, the Committee for Medicinal Products for 
Human Use (CHMP) of the European Medicines Agency 
(EMA) released guidelines on the risk of NSF associated 
with gadolinium-based contrast media, placing macrocyclic 
compounds in the low-risk category (Table 4).80 In simi-
lar initiatives, the U.S. Food and Drug Administration and 
the European Society of Urogenital Radiology (ESUR) also 
placed macrocyclic agents in the lowest-risk group for devel-
opment of NSF.81,82
Growing awareness of NSF has been accompanied by a 
decline in the number of reported cases. For children, in par-
ticular, incidences of NSF appear to be very rare.83,84
Adverse events/adverse drug reactions. The safety margin 
for diagnostic drugs should be high, particularly for those 
used in pediatric patients. The published literature, reflecting 
primarily adult MRI experience, reports that adverse reactions 
occur at low rates and are qualitatively similar for current 
gadolinium-based contrast media, regardless of molecular 
structure.85–88 Common adverse drug reactions (ADRs) 
include nausea, vomiting, and hives.
Assessments of AEs and ADRs in pediatric MRI are more 
problematic, reflecting the low number of age-specific studies 
when compared with adult MRI. In the absence of extensive 
clinical study data, perceptions on the safety and tolerability 
of contrast media in pediatric MRI may be informed by per-
sonal experience. AEs have been reported to occur at low rates 
in individual studies of gadodiamide, gadobutrol, gadobenate 
dimeglumine, gadopentetate, and gadoversetamide in pediat-
ric patients of different ages, while a retrospective chart review 
reported that allergic-like reactions to gadolinium-containing 
contrast media were rare.72,89–92 A recent safety study of gado-
butrol in 130 patients aged 2 to 17 years75 reported a tolerability 
profile that was comparable with adult experience,88 with low 
rates of AEs that were mostly mild to moderate in intensity.
Bhargava et al
104 Magnetic Resonance insights 2013:6
Ta
bl
e 
3.
 P
ro
pe
rt
ie
s 
an
d 
ap
pr
ov
al
 s
ta
tu
s 
of
 e
xt
ra
ce
llu
la
r g
ad
ol
in
iu
m
-b
as
ed
 c
on
tra
st
 a
ge
nt
s.
a
C
H
EM
IC
A
L 
N
A
M
E
TR
A
D
E 
N
A
M
E
M
A
N
U
FA
C
-
TU
R
ER
C
H
A
R
G
E 
A
N
D
 
C
H
EM
IC
A
L 
ST
R
U
C
TU
R
E
C
O
N
C
EN
-
TR
AT
IO
N
 
(m
ol
/L
)
K
IN
ET
IC
ST
A
B
IL
IT
Yb
 R
EL
A
X
IV
IT
Y 
(3
 T
 IN
 
PL
A
SM
A
, 3
7O
C
) 
[L
/m
m
ol
-1
s-
1 ]
T1
 S
H
O
R
TE
N
IN
G
 T
IM
E 
(M
S)
 IN
 B
LO
O
D
 F
O
R
  
1 
m
L/
L 
A
G
EN
T
V
IS
C
O
SI
TY
 
[m
Pa
*s
]
 
O
SM
O
LA
LI
TY
 
[m
O
sm
/k
g 
H
2O
]
EX
C
R
ET
IO
N
R
EC
O
M
M
EN
D
ED
 
D
O
SE
S 
FO
R
 
IM
A
G
IN
G
  
(m
m
ol
/k
g)
A
PP
R
O
VE
D
 
D
O
SE
S 
FO
R
 
C
H
IL
D
R
EN
 
(m
m
ol
/k
g)
g
ad
od
ia
m
id
e
o
m
ni
sc
an
g
e
h
ea
lth
ca
re
n
on
io
ni
c
lin
ea
r
0.
5
35
 s
4.
0
88
0.
85
1.
4
79
0
R
en
al
B
od
y 
0.
1
c
n
s
 0
.1
K
id
ne
y 
0.
05
in
tra
th
or
ac
ic
, 
in
tra
-a
bd
om
i-
na
l, 
pe
lv
ic
 0
.1
Fr
om
 2
 
ye
ar
s:
 0
.1
g
ad
op
en
-
te
ta
te
di
m
eg
lu
m
in
e
M
ag
ne
vi
st
B
ay
er
io
ni
c
lin
ea
r
0.
5
10
 m
in
3.
7
86
4.
80
2.
9
19
60
R
en
al
c
n
s
 0
.1
e
xt
ra
cr
an
ia
l/
ex
tra
sp
in
al
 0
.1
B
od
y 
0.
1
Fr
om
 2
 
ye
ar
s:
 0
.1
g
ad
ob
en
at
e
di
m
eg
lu
m
in
e
M
ul
tih
an
ce
B
ra
cc
o
io
ni
c
lin
ea
r
0.
5
n
/a
5.
5
96
0.
96
5.
3
19
70
R
en
al
, 
4–
5%
 
he
pa
to
bi
li-
ar
y
c
n
s
 0
.1
M
R
a
 0
.1
Fr
om
 2
 
ye
ar
s:
 0
.1
g
ad
ov
er
se
t-
am
id
e
o
pt
iM
a
R
K
ty
co
n
on
io
ni
c
lin
ea
r
n
ot
 
ap
pr
ov
ed
<1
8 
ye
ar
s
g
ad
ot
er
at
e
m
eg
lu
m
in
e
D
ot
ar
em
g
ue
rb
et
io
ni
c
cy
cl
ic
0.
5

1
m
on
th
3.
5
85
9.
0
2.
0
13
50
R
en
al
c
n
s
 0
.1
e
xt
ra
cr
an
ia
l/
ex
tra
sp
in
al
 0
.1
B
od
y 
0.
1
in
fa
nt
s 
an
d 
ch
il-
dr
en
: 0
.1
g
ad
ot
er
id
ol
P
ro
h
an
ce
B
ra
cc
o
n
on
io
ni
c
cy
cl
ic
0.
5
3 
h
3.
7
87
0.
33
1.
3
63
0
R
en
al
c
n
s
 0
.1
e
xt
ra
cr
an
ia
l/
ex
tra
sp
in
al
 0
.1
Fr
om
 2
 
ye
ar
s:
 0
.1
g
ad
ob
ut
ro
l
g
ad
ov
is
t, 
g
ad
av
is
t
B
ay
er
n
on
io
ni
c
cy
cl
ic
Fr
om
 2
 
ye
ar
s:
 0
.1
g
ad
ox
et
ic
 
ac
id
P
rim
ov
is
t
B
ay
er
io
ni
c
lin
ea
r
0.
5
n
/a
6.
2
n
/a
1.
19
66
8
50
%
 
re
na
l, 
50
%
 h
ep
-
at
ob
ili
ar
y
Li
ve
r 0
.0
25
n
ot
 
ap
pr
ov
ed
<1
8 
ye
ar
s
a P
le
as
e 
co
ns
ul
t y
ou
r l
oc
al
 p
re
sc
rib
in
g 
in
fo
rm
at
io
n 
fo
r t
he
 la
te
st
 in
fo
rm
at
io
n 
on
 a
pp
ro
ve
d 
in
di
ca
tio
ns
 a
nd
 d
os
in
g.
b K
in
et
ic
 s
ta
bi
lit
y:
 d
is
so
ci
at
io
n 
ha
lf-
lif
e 
at
 p
h
 1
.0
.
1.
0
  2
4 
h
   
  5
.0
10
36
.9
6
   
  4
.9
6
   
   
  1
39
0
  R
en
al
   
   
  c
ns
 0
.1
Li
ve
r 0
.1
Ki
dn
ey
 0
.1
M
Ra
 0
.1
W
ho
le
 b
od
y 
(e
U)
 0
.1
0.
5 
   
 
  n
/a
 
   
  4
.5
   
   
   
   
   
   
   
  n
/a
   
   
   
   
   
   
   
   
   
   
 2
.0
   
   
   
   
   
11
10
   
   
   
   
   
   
 R
en
al
   
   
   
   
cn
s 
0.
1 
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
  L
iv
er
 0
.1
Review of MRI in pediatric patients
105Magnetic Resonance insights 2013:6
Figure 3. comparative rates of gadolinium ion release for 1 molar solutions of gadolinium-based contrast media in serum from healthy volunteers at 
37°c. Reproduced from thomas Frenzel, Philipp Lengsfeld, heiko schirmer, Joachim hütter, hanns-Joachim Weinmann, stability of gadolinium-Based 
Magnetic Resonance imaging contrast agents in human serum at 37°c, invest Radiol, 2008;43:817–828 with permission from Wolters Kluwer health.
Table 4. Gadolinium-based contrast media classified according to 
chMP categorization of nsF risk (chMP 2009).80
•	 High risk: gadoversetamide, gadodiamide, gadopentetate 
dimeglumine
•	 Medium risk: gadofosveset trisodium, gadoxetate disodium, 
gadobenate dimeglumine
•	 Low risk: gadoterate meglumine, gadoteridol, gadobutrol
Abbreviations: chMP, committee for Medicinal Products for human Use; 
NSF, nephrogenic systemic fibrosis.
Pharmacologic profile. The currently available 
gadolinium-based contrast media display similar pharmaco-
kinetic profiles in adults.93 Pharmacokinetic studies in 
children aged 2 and older have included the 0.5 molar agent, 
gadoversetamide,72,74 and the 1 molar agent, gadobutrol.75 
These studies concluded that individual differences in 
pharmacokinetics (total body clearance and central volume 
of distribution) were attributable to body weight, with no 
additional effect from age (Fig. 4). Dosage based on body 
weight—as in adults—is therefore appropriate in children 
aged 2 and older, and no age-dependent dose adjustment is 
required. Experience of gadobutrol use in children under 
2  years indicates that standard weight-adjusted dosing is 
feasible also with gadobutrol in this age-group.76
In summary, safety considerations are a priority when 
selecting a gadolinium-based contrast medium for contrast-
enhanced MRI. From this perspective, macrocyclic contrast 
agents (gadobutrol, gadoterate meglumine, or gadoteridol) 
are preferred for pediatric use, particularly in relation to the 
potential risk of NSF, even if theoretical in most patients.
Efficacy. The efficacy of a contrast medium—ie, its 
capacity to enhance image quality—represents an important 
consideration. Individual contrast media have demonstrated 
differences in efficacy in adult studies.
The characteristics of an MRI contrast medium that deter-
mine its efficacy include its effect on shortening the T1 relax-
ation time. In dynamic examinations, the T1 relaxation time 
is also related to the gadolinium concentration of the solution. 
Gadolinium-containing contrast media with high T1 relax-
ivity (gadobenate dimeglumine and gadobutrol) demonstrate 
excellent image quality in adult  studies.94–97 The majority of 
gadolinium-based contrast media are available as 0.5 molar 
formulations, while gadobutrol is a new- generation contrast 
medium available as a 1 molar formulation. An  additional 
advantage of a higher gadolinium  concentration is that a 
smaller injection volume may be used, which enables a more 
compact bolus geometry that is favorable for dynamic MRI 
procedures such as perfusion examinations and MRA.98–100
Data on the comparative efficacy of contrast media are 
available from preclinical studies and clinical  studies in 
adults.95,99,101–108 In intraindividual trials, gadobenate dimeglu-
mine demonstrated superior lesion enhancement and diagnostic 
information relative to gadopentetate or  gadodiamide,106,107,109 
which is explainable by the higher relaxivity of gadobenate. 
In similarly designed trials, gadobutrol demonstrated superior 
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Figure 4. simulated gadolinium concentrations in plasma 20 minutes after injection of 0.1 mmol/kg body weight gadobutrol in four subjects of different 
ages represented by typical body weight. Boxes represent interquartile range, with the center horizontal line at median. Whiskers extend to data nearest 
to a distance of at most 1.5 times the interquartile range. Reproduced from gabriele hahn, ina sorge, Bernd gruhn, Katja glutig, Wolfgang hirsch, Ravi 
Bhargava, Julia Furtner, Mark Born, cronelia schroder, hakan ahlstrom, sylvie Kaiser, Jorg Detlev Moritz, christian Wilhelm Kunze, Manohar shroff, eira 
stokland, Zuzana Jirakova trnkova, Marcus schultze-Mosgau, stefanie Reif, claudia Bacher-stier, hans-Joachim Mentzel, Pharmacokinetics and safety 
of gadobutrol-enhanced Magnetic Resonance imaging in Pediatric Patients, invest Radiol, 2009;44:776-783 with permission from Wolters Kluwer health.
performance, including enhanced lesion detection and conspi-
cuity, compared with the 0.5 molar agents gadopentetate and 
gadoterate meglumine, again attributable to the higher relax-
ivity of gadobutrol.96,101,110
Current guidelines indicate that efficacy results for con-
trast media in adult studies can be extrapolated to pediatric 
populations with the same indications.111 In support, a study 
of pediatric subjects aged 2 to 17 years confirmed the compa-
rable efficacy of 1 molar gadobutrol in this population as in 
adults.75 The same may apply when comparing younger and 
older pediatric patients with similar disease processes.111
One study has directly compared contrast media for 
imaging brain and spine tumors in children, reporting signifi-
cant superiority for gadobenate dimeglumine over gadopen-
tetate in lesion visualization.112 Additional studies comparing 
the efficacy of contrast media in pediatric patients will aid 
practice in future. Experience in clinical practice supports the 
trial evidence of differences in efficacy between contrast media 
(see case study in Fig. 5).
Practical suggestions for the use of contrast media in 
pediatric MRI are summarized in Table 5.
Consensus statements.
Formulation. Gadolinium-containing contrast media are 
available at 0.5 molar concentrations, with the exception of 
the 1 molar agent, gadobutrol.
Safety. Safety is the primary consideration when 
selecting a contrast medium in pediatric MRI. Macrocyclic 
compounds (gadobutrol, gadoterate meglumine, and 
gadoteridol) are the most stable class of contrast media and 
are associated with lowest risk of NSF. Trial evidence on 
safety is available for a limited number of contrast media in 
pediatric MRI, but clinical experience indicates a similarity 
to adult profiles.
Efficacy. Signal enhancement in contrast-enhanced MRI 
is associated in adult studies to the T1 shortening effect, which 
is a function of relaxivity and, in dynamic scans, gadolinium 
concentration. Gadobutrol demonstrates superior lesion 
detection and conspicuity compared with 0.5 molar agents with 
a lower relaxivity in adult studies. The relationship between 
relaxivity and efficacy may also apply in pediatric imaging. 
Optimal SNR for dynamic MRI procedures may be provided 
by a high-concentration, tight bolus injection of contrast 
medium.
Conclusions
MRI, frequently with contrast enhancement, offers definitive 
diagnostic imaging, treatment guidance, and monitoring for 
a wide range of conditions, at low risk to the pediatric patient. 
Pediatric radiologists should assess the needs of patients 
individually, drawing on the available literature, personal 
experience, and the opinions of colleagues. To guide practice 
in the future, there is a need for more evidence-based deci-
sion making, founded on well-performed, pediatric- specific 
trials. The continued introduction of novel technologies and 
protocols, and the optimized use of contrast enhancement, 
are predicted to further increase applications of MRI in 
children.
Summary of expert meeting recommendations.
Advantages of MRI in pediatric radiology.
•	 MRI has advantages over ionizing-radiation modalities 
in safety and efficacy for a range of indications and organ 
systems.
•	 MRI provides high-resolution images of tissue anatomy 
in multiple planes, with the capability to perform quanti-
tative functional imaging.
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Figure 5. Neurofibromatosis type II diagnosed in 15-year-old girl with multiple cutaneous tumors and meningeal tumors. Technique: head coil, 1.5 T, Gd 
(gadopentetate dimeglumine or gadobutrol) by manual injection. Protocol: t2 tse, t1, t1 gd. slice thickness 3–5 mm. transverse (A, t1; B, t1 gd), 
coronal (C, t1 gd), and sagittal views (D, t2; E, t1; F and G, t1 gd with gadopentetate dimeglumine and gadobutrol, respectively). Findings: strong 
contrast enhancement in internal auditory canal. a high relaxivity agent (gadobutrol, 5 ml) showed strong enhancement in the cervical myelon (g vs. F). 
Conclusions: MRI assisted to diagnose schwannoma of the vestibular nerve at both hemispheres and also intraspinal neurofibroma. Notably, gadobutrol 
provided greater imaging efficacy than gadopentetate dimeglumine. Courtesy Professor H-J Mentzel.
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Table 5. Practical suggestions for pediatric MRi: contrast medium 
use.
•	 Use of gadolinium-containing contrast media should not be 
a problem in patients with normal renal function according 
to age 
•	 Base dose on the child’s weight, not age 
•	 Weight should be measured, not estimated
•	 syringes should allow precise dosing, eg, 1 mL insulin 
syringes are recommended for young infants
•	 injection technique (manual vs. automated) is age- 
dependent
•	 contrast injection uses a 22 or 24 gauge needle
•	 Prior to injection of contrast, the intravenous line is flushed 
with saline to clear the line.  contrast of 0.1 mL/kg is injected 
at a rate of 0.5 mL/sec
•	 A saline flush of sufficient volume to clear the intravenous 
line post-contrast administration should be injected at a rate 
of 0.5 mL/sec
•	 Bolus timing is affected by heart rate, cardiac output, and 
injection site and is therefore unpredictable. Bolus monitor-
ing is recommended
•	 Renal function (ie, estimated glomerular filtration rate) 
should be determined in patients at risk, such as:  
•	 children with known renal disease 
•	 children on medication toxic to the kidneys, eg, oncol-
ogy patients on treatment  
•	 children with dehydration
•	 children with complex diseases also affecting the 
kidneys 
•	 children who received iodinated contrast media in the 
last 24 hours 
•	 in children with severely reduced renal function, MRi with-
out intravenous contrast or an alternative method should be 
considered
•	 Safety concerns regarding risk/benefit assessment remain 
the responsibility of the treating clinician and local label indi-
cations should be observed
Abbreviation: MRi, magnetic resonance imaging. 
Practical issues in pediatric MRI.
Preparation.
•	 Prior to the scan, the patient (with parent or guardian) 
should be familiarized with the examination to alleviate 
anxiety and reduce movement during the examination.
•	 Younger children may be encouraged into natural sleep 
during the examination.
•	 Decisions to use sedation or general anesthesia should be 
made on an individual patient basis, taking into account 
the benefits and risks.
Equipment and protocol.
•	 For optimized imaging, coil sizes should be selected 
according to the area of interest.
•	 The scanner should be 1.5 T at minimum, and preferably 
3 T.
•	 Protocols should be individualized according to the 
patient’s age and imaging indication.
Criteria for use of contrast enhancement in pediatric MRI.
•	 Gadolinium-based contrast media: (1) aid the localiza-
tion, characterization, and staging of lesions/tumors, 
(2)  help differentiate inflammatory and infective 
 disorders, and (3) allow MRA.
•	 Contrast media are increasing the diagnostic value of the 
MR examination in many situations. In children with 
severely impaired renal function or on dialysis, or in very 
young children, contrast medium use should be subjected 
to careful risk/benefit assessment. For these groups, 
unenhanced MRI or other imaging techniques should be 
considered.
Considerations in choice of contrast medium.
•	 Gadolinium-containing contrast media are available 
at a 0.5 molar concentration, with the exception of the 
1 molar agent, gadobutrol.
•	 Safety is the primary consideration when selecting a con-
trast medium, preferably based on trial evidence. Mac-
rocyclic agents (gadobutrol, gadoterate meglumine, and 
gadoteridol) have the highest chelate stability, associated 
with reduced gadolinium ion release.
•	 Efficacy (image quality) that is confirmed in compara-
tive trials is desirable. The signal intensity of a contrast 
medium is shown in adult studies to depend on its effect 
on T1 relaxivity.
•	 Gadobutrol is the gadolinium-containing  contrast med-
ium with the highest relaxivity among the macrocyclic 
agents.
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Figure 6. 15 year old with aortic and superior mesenteric artery stenosis 
secondary to neurofibromatosis. Maximal intensity projections of the 
subtracted contrast-enhanced ViBe sequences show focal narrowing of 
the abdominal aorta (arrow) at the level of the renal arteries in coronal 
(A) and sagittal (B) projections. the sagittal image also shows focal 
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